{"id":"ribociclib-plus-aromatase-inhibitor","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Diarrhea"},{"rate":"20-40%","effect":"Fatigue"},{"rate":"10-30%","effect":"Nausea"},{"rate":"10-30%","effect":"Vomiting"},{"rate":"10-30%","effect":"Leukopenia"},{"rate":"5-20%","effect":"Neutropenia"},{"rate":"5-20%","effect":"Thrombocytopenia"},{"rate":"5-20%","effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By blocking CDK4/6, ribociclib prevents the progression of the cell cycle, thereby inhibiting the growth and proliferation of cancer cells. This is particularly effective in combination with aromatase inhibitors, which reduce estrogen levels in the body, further inhibiting cancer cell growth.","oneSentence":"Ribociclib works by inhibiting CDK4/6, which are proteins that help cancer cells grow and divide.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:32:08.220Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic breast cancer in postmenopausal women with estrogen receptor-positive (ER+) and human epidermal growth factor receptor 2-negative (HER2-) disease"}]},"trialDetails":[{"nctId":"NCT06930859","phase":"","title":"Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in Russia","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-12-22","conditions":"Breast Cancer","enrollment":2766},{"nctId":"NCT07085767","phase":"PHASE3","title":"Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer","status":"RECRUITING","sponsor":"Olema Pharmaceuticals, Inc.","startDate":"2025-11-03","conditions":"Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer","enrollment":1000},{"nctId":"NCT02712723","phase":"PHASE2","title":"Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Qamar Khan","startDate":"2016-02","conditions":"Breast Cancer","enrollment":121},{"nctId":"NCT06830720","phase":"","title":"A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-02-20","conditions":"Breast Neoplasms","enrollment":3250},{"nctId":"NCT05768139","phase":"PHASE1, PHASE2","title":"First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2023-04-17","conditions":"Breast Cancer, Solid Tumors, Adult","enrollment":720},{"nctId":"NCT07423611","phase":"PHASE2","title":"ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-10-01","conditions":"Breast Cancer","enrollment":388},{"nctId":"NCT06905301","phase":"","title":"Implementation Study to Describe and Compare Retention Rate and Adherence to Adjuvant Therapy With Ribociclib With and Without Usage of Mobile Application in Patients With HR+ HER2-negative Stage II and III Breast Cancer in Real-world Practice","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-01-23","conditions":"Breast Cancer","enrollment":240},{"nctId":"NCT07400523","phase":"PHASE3","title":"Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2026-02-10","conditions":"Breast Cancer","enrollment":446},{"nctId":"NCT06311383","phase":"","title":"A Non-interventional Study for Women With HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer to Evaluate the Real-world Effectiveness of Treatment Algorithms Beginning With Ribociclib + AI/FUL, or With Endocrine Therapy or Chemotherapy as First Line Treatment","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-10-09","conditions":"Breast Cancer","enrollment":2610},{"nctId":"NCT04964934","phase":"PHASE3","title":"Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-06-30","conditions":"ER-Positive HER2-Negative Breast Cancer","enrollment":315},{"nctId":"NCT05826964","phase":"PHASE2","title":"Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2023-06-12","conditions":"Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer","enrollment":24},{"nctId":"NCT07037199","phase":"PHASE2","title":"Efficacy and Safety of Trastuzumab Rezetecan Followed by CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-08-18","conditions":"Advanced Breast Cancer","enrollment":45},{"nctId":"NCT04943497","phase":"","title":"A Prospective Observational Study to Describe Clinical Outcomes, Treatment Patterns, Patients Characteristics Among Patients With HR+/HER2- Advanced BC Initiating Treatment With Risarg®, Piqray®, Endocrine Therapy or Chemotherapy in Routine Clinical Practice in Russia","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-07-27","conditions":"Breast Cancer","enrollment":2424},{"nctId":"NCT06495164","phase":"","title":"A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-06-24","conditions":"Breast Cancer, Malignant Neoplasm of Breast","enrollment":1},{"nctId":"NCT05867251","phase":"PHASE1, PHASE2","title":"Study of AVZO-021 in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Avenzo Therapeutics, Inc.","startDate":"2023-08-30","conditions":"Advanced Solid Tumor, HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer","enrollment":430},{"nctId":"NCT03822468","phase":"PHASE2","title":"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-06-11","conditions":"Breast Cancer","enrollment":376},{"nctId":"NCT03425838","phase":"PHASE3","title":"Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Borstkanker Onderzoek Groep","startDate":"2017-11-09","conditions":"Breast Neoplasm Female","enrollment":1050},{"nctId":"NCT07072013","phase":"","title":"An Indirect Treatment Comparison of the Effectiveness of Ribociclib Combined With Non-steroidal Aromatase Inhibitors vs. Tamoxifen for the Adjuvant Treatment of Premenopausal Women With Hormon Receptor-positive, HER2-negative Early Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-09-08","conditions":"Breast Cancer","enrollment":1937},{"nctId":"NCT07005557","phase":"PHASE3","title":"Chemo-free in Older (≥65) Node-Positive ER+/HER2- Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-06-15","conditions":"Breast Cancer, Adjuvant Therapy","enrollment":1244},{"nctId":"NCT06996093","phase":"PHASE3","title":"Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-06-02","conditions":"Breast Cancer","enrollment":2508},{"nctId":"NCT04660435","phase":"","title":"To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer","status":"RECRUITING","sponsor":"Fondazione Sandro Pitigliani","startDate":"2020-09-01","conditions":"Metastatic Breast Cancer, ER Positive Breast Cancer, HER2-negative Breast Cancer","enrollment":150},{"nctId":"NCT03944434","phase":"PHASE2","title":"FACILE: FeAsibility of First-line RiboCIclib in OLdEr Patients with Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Sandro Pitigliani","startDate":"2018-12-27","conditions":"Breast Cancer","enrollment":116},{"nctId":"NCT05384119","phase":"PHASE1","title":"Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer","status":"TERMINATED","sponsor":"Tvardi Therapeutics, Incorporated","startDate":"2023-01-09","conditions":"Breast Cancer","enrollment":6},{"nctId":"NCT04256941","phase":"PHASE2","title":"Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-05-31","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8","enrollment":4},{"nctId":"NCT03227328","phase":"PHASE2","title":"CDK4/6-inhibitor or Chemotherapy, in Combination with ENDOcrine Therapy, for Advanced Breast Cancer / KENDO","status":"COMPLETED","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2017-08-02","conditions":"Hormone Receptor Positive Breast Cancer, Metastatic Breast Cancer, Hormone Receptor Negative Breast Cancer","enrollment":52},{"nctId":"NCT03839823","phase":"PHASE2","title":"Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-02-25","conditions":"Breast Cancer","enrollment":222},{"nctId":"NCT06481956","phase":"PHASE2","title":"T-DM1 Combined With CDK4/6 Inhibitor Ribociclib","status":"ENROLLING_BY_INVITATION","sponsor":"Zheng Yabing","startDate":"2023-10-25","conditions":"HER2-positive Advanced Breast Cancer","enrollment":40},{"nctId":"NCT02278120","phase":"PHASE3","title":"Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-11-20","conditions":"Advanced Metastatic Breast Cancer","enrollment":672},{"nctId":"NCT03477396","phase":"PHASE2","title":"Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2018-06-14","conditions":"Estrogen Receptor and/or Progesterone Receptor Positive, HER2/Neu Negative, Stage IV Breast Cancer AJCC v6 and v7","enrollment":2},{"nctId":"NCT03462251","phase":"PHASE3","title":"Ribociclib and Endocrine Therapy or Chemotherapy With or Without Bevacizumab for Metastatic Breast Cancer in First Line","status":"COMPLETED","sponsor":"iOMEDICO AG","startDate":"2018-05-24","conditions":"Breast Cancer, Hormone Receptor Positive Tumor, HER 2 Negative Breast Cancer","enrollment":41},{"nctId":"NCT05569187","phase":"","title":"Ribociclib in Combination With Non-steroidal Aromatase Inhibitors in Patients With Advanced Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-03-23","conditions":"Breast Cancer","enrollment":76},{"nctId":"NCT02734615","phase":"PHASE1","title":"Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-06-14","conditions":"Advanced or Metastatic ER+ Breast Cancer","enrollment":199},{"nctId":"NCT04852081","phase":"","title":"Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.","status":"UNKNOWN","sponsor":"Blokhin's Russian Cancer Research Center","startDate":"2021-01-01","conditions":"Breast Cancer Stage IV","enrollment":1000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":34,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Ribociclib plus aromatase inhibitor","genericName":"Ribociclib plus aromatase inhibitor","companyName":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","companyId":"sun-yat-sen-memorial-hospital-of-sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ribociclib works by inhibiting CDK4/6, which are proteins that help cancer cells grow and divide. Used for Advanced or metastatic breast cancer in postmenopausal women with estrogen receptor-positive (ER+) and human epidermal growth factor receptor 2-negative (HER2-) disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}